Seminar – Feng-Chun Yang, M.D., Ph.D.
Event Date & TimeDecember 1, 2021 at 12 Noon
DEPARTMENT OF PHARMACOLOGY
Wednesday, December 1, 2021
12:00pm – Virtual Presentation
Feng-Chun Yang, M.D., Ph.D.
Department of Cell Systems & Anatomy
The A.B. Alexander Distinguished Chair in Cancer Research, Mays Cancer Center
UT Health San Antonio
San Antonio, Texas
Save to CalendarAdd to Calendar
About the Speaker(s)
Dr. Yang’s laboratory has been focused on investigating the cellular/molecular mechanisms of hematopoietic malignancies, with a specific focus on mutations of ASXL1, ASXL2, PHF6 and NF1 in the pathogenesis of myeloid malignancies. Alteration of ASXL1 gene is frequent in multiple forms of myeloid malignancies, including myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), MDS/MPN (such as CMML and JMML), and acute myeloid leukemia (AML). In contrast, ASXL2 mutations are restricted to patients with t(8;21) AML patients both in children and adults at an incident of 23%. Interestingly, ASXL1 and ASXL2 mutations are mutually exclusive in t(8;21) AML. However, the role of ASXL1/ASXL2 in the pathogenesis of myeloid malignancies and in normal hematopoiesis remains largely unknown. Mutations in NF1 tumor suppressor gene cause the common genetic disorder neurofibromatosis type 1 (NF1) which is associated with a predisposition to JMML, MDS and AML. Our goal is to identify the therapeutic targets for the treatment of these gene mutation-mediated myeloid malignancies.